

# Patrizia Carrieri

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/5647412/patrizia-carrieri-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

225  
papers

5,797  
citations

38  
h-index

68  
g-index

239  
ext. papers

6,887  
ext. citations

5  
avg, IF

5.09  
L-index

#	Paper	IF	Citations
225	Evaluation of a novel therapeutic education programme for people with alcohol use disorder in France: a mixed-methods intervention study protocol (ETHER).. <i>Harm Reduction Journal</i> , <b>2022</b> , 19, 2	4.6	0
224	Peer presence and familiarity as key factors to reduce cocaine intake in both rats and humans: an effect mediated by the subthalamic nucleus.. <i>Psychopharmacology</i> , <b>2022</b> , 239, 1097	4.7	0
223	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort).. <i>Clinical Nutrition</i> , <b>2022</b> , 41, 610-619	5.9	3
222	Use of psychoactive substances by night-shift hospital healthcare workers during the first wave of the COVID-19 pandemic: a cross-sectional study based in Parisian public hospitals (ALADDIN).. <i>BMJ Open</i> , <b>2022</b> , 12, e055699	3	1
221	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors.. <i>JHEP Reports</i> , <b>2022</b> , 4, 100481	10.3	
220	HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data).. <i>AIDS Research and Therapy</i> , <b>2022</b> , 19, 15	3	0
219	Incidence of cervical, breast and colorectal cancers between 2010 and 2015 in people living with HIV in France.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0261069	3.7	2
218	Impact of the COVID-19 crisis on healthcare workers: The need to address quality of working life issues.. <i>Respirology</i> , <b>2022</b> , 27, 469-471	3.6	1
217	Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , <b>2021</b> ,	7.9	0
216	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet, The</i> , <b>2021</b> ,	40	12
215	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
214	HCV Cure and Cannabis Abstinence Facilitate Tobacco Smoking Quit Attempts in HIV-HCV Co-Infected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>AIDS and Behavior</i> , <b>2021</b> , 25, 4141-4153	4.3	2
213	European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , <b>2021</b> , 3, 100234	10.3	13
212	Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV. <i>Nature Communications</i> , <b>2021</b> , 12, 4450	17.4	10
211	Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 37-47	13.4	7
210	Effectiveness of direct-acting antivirals for chronic hepatitis C treatment in migrant and non-migrant populations in France. <i>Liver International</i> , <b>2021</b> , 41, 2328-2340	7.9	1
209	Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). <i>Expert Review of Anti-Infective Therapy</i> , <b>2021</b> , 19, 1147-1156	5.5	1

208	Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis. <i>HIV Medicine</i> , <b>2021</b> , 22, 924-935	2.7	1
207	Post-HCV cure self-reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1665-1667	3.4	1
206	Social vulnerability of patients co-infected with hepatitis B and hepatitis delta viruses: Data from the ANRS CO22 HEPATHER cohort. <i>Journal of Clinical Virology</i> , <b>2021</b> , 144, 104987	14.5	1
205	Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). <i>Liver International</i> , <b>2021</b> ,	7.9	1
204	Hepatitis B in Senegal: A Successful Infant Vaccination Program but Urgent Need to Scale Up Screening and Treatment (ANRS 12356 AmBASS survey).. <i>Hepatology Communications</i> , <b>2021</b> ,	6	1
203	"Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2020</b> , 81, 102766	5.5	12
202	Correlates of Self-Reported Cotton Fever Experience among People Who Inject Opioids. <i>Substance Use and Misuse</i> , <b>2020</b> , 55, 1021-1027	2.2	0
201	Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM). <i>BMC Infectious Diseases</i> , <b>2020</b> , 20, 49	4	2
200	Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. <i>Aids</i> , <b>2020</b> , 34, 953-954	3.5	2
199	Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfecting patients (ANRS CO13 HEPAVIH). <i>Journal of Hepatology</i> , <b>2020</b> , 72, 588-591	13.4	6
198	Alcohol Use Patterns and Liver Outcomes: Is There Really a Difference Between Drinking Beer and Drinking Wine?. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 1650-1651	6.9	
197	Patient-reported outcomes to enhance person-centred HIV care. <i>Lancet HIV,the</i> , <b>2020</b> , 7, e59-e68	7.8	33
196	Hepatitis C virus-microelimination program and patient trajectories after hepatitis C virus cure in an outpatient HIV clinical unit. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 1212-1221	2.2	3
195	Cannabis use is associated with a lower risk of diabetes in chronic hepatitis C-infected patients (ANRS CO22 Hepather cohort). <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1473-1483	3.4	5
194	Life after hepatitis C cure in HIV-infected people who inject drugs and men who have sex with men treated with direct-acting antivirals in France: Health perceptions and experiences from qualitative and quantitative findings (ANRS CO13 HEPAVIH). <i>Journal of Viral Hepatitis</i> , <b>2020</b> , 27, 1462-1472	3.4	4
193	Coffee Intake and Neurocognitive Performance in HIV/HCV Coinfected Patients (ANRS CO13 HEPAVIH). <i>Nutrients</i> , <b>2020</b> , 12,	6.7	2
192	Elevated Fatty Liver Index as a Risk Factor for All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis C Virus-Coinfected Patients (ANRS CO13 HEPAVIH Cohort Study). <i>Hepatology</i> , <b>2020</b> , 71, 1182-1197	11.2	4
191	Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study). <i>Addiction</i> , <b>2020</b> , 115, 573-582	4.6	7

190	HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort). <i>AIDS and Behavior</i> , <b>2020</b> , 24, 1069-1084	4.3	5
189	France removes hepatitis C treatment prescriber restrictions-But what is the impact of the delay for key populations?. <i>Liver International</i> , <b>2019</b> , 39, 2418-2419	7.9	1
188	Prevention and care of hepatitis B in the rural region of Fatick in Senegal: a healthcare workers' perspective using a mixed methods approach. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 627	2.9	5
187	Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project. <i>International Journal of Drug Policy</i> , <b>2019</b> , 72, 61-68	5.5	10
186	Screening, diagnosis and care cascade for viral hepatitis B and C in Yaoundé, Cameroon: a qualitative study of patients and health providers coping with uncertainty and unbearable costs. <i>BMJ Open</i> , <b>2019</b> , 9, e025415	3	12
185	Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol. <i>BMJ Open</i> , <b>2019</b> , 9, e023683	3	3
184	Methadone in primary care in France: Using evidence for action against hepatitis C. <i>International Journal of Drug Policy</i> , <b>2019</b> , 71, 91-92	5.5	1
183	Factors Associated with Virological Rebound in HIV-Positive Sub-Saharan Migrants Living in France After Traveling Back to Their Native Country: ANRS-VIHVO 2006-2009 Study. <i>Journal of Immigrant and Minority Health</i> , <b>2019</b> , 21, 1342-1348	2.2	2
182	Burden and impacts of chronic hepatitis B infection in rural Senegal: study protocol of a cross-sectional survey in the area of Niakhar (AmBASS ANRS 12356). <i>BMJ Open</i> , <b>2019</b> , 9, e030211	3	7
181	No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study). <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 274-276	2.2	2
180	Interventions to address substance use and sexual risk among gay, bisexual and other men who have sex with men who use methamphetamine: A systematic review. <i>Drug and Alcohol Dependence</i> , <b>2019</b> , 194, 410-429	4.9	26
179	Letter to the Editor: Patient-Reported Outcomes for Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis: Rationale for Expanded Use. <i>Hepatology</i> , <b>2019</b> , 70, 443-444	11.2	1
178	Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 402-411	13.4	77
177	Reply to: "Coffee consumption and decreased all-cause mortality - What is the true estimate of effect?". <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1106	13.4	
176	The need for patient-tailored dosing of baclofen in future clinical trials. <i>European Neuropsychopharmacology</i> , <b>2018</b> , 28, 656-657	1.2	3
175	Importance of the patient-physician interaction in assessing acceptability of HIV cure trials. <i>HIV Medicine</i> , <b>2018</b> , 19, e56-e57	2.7	6
174	Impact of an educational intervention on risks associated with drug injection, and on psychosocial factors (PSF) involved in initiating and maintaining new health behaviors over time. <i>Addictive Behaviors</i> , <b>2018</b> , 87, 222-230	4.2	2
173	Profile, risk practices and needs of people who inject morphine sulfate: Results from the ANRS-AERLI study. <i>International Journal of Drug Policy</i> , <b>2018</b> , 59, 3-9	5.5	0

172	Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199874	3.7	2
171	Impact of Alcohol and Coffee Intake on the Risk of Advanced Liver Fibrosis: A Longitudinal Analysis in HIV-HCV Coinfected Patients (ANRS HEPAVIH CO-13 Cohort). <i>Nutrients</i> , <b>2018</b> , 10,	6.7	15
170	Factors associated with perceived loss of libido in people who inject opioids: Results from a community-based survey in France. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 190, 121-127	4.9	9
169	Daily cannabis and reduced risk of steatosis in human immunodeficiency virus and hepatitis C virus-co-infected patients (ANRS CO13-HEPAVH). <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 171-179	3.4	14
168	Posttraumatic Stress Disorder as a Significant Correlate of Voluntary Antiretroviral Treatment Interruption in Adult HIV-Infected Patients Followed up in French Hospitals: Data From the ANRS-VESPA2 National Survey. <i>Journal of Clinical Psychiatry</i> , <b>2018</b> , 79,	4.6	3
167	Factors associated with DAA virological treatment failure and resistance-associated substitutions description in HIV/HCV coinfecting patients. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 856-866	3.4	6
166	The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 845-847	13.4	3
165	Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study). <i>HIV Medicine</i> , <b>2018</b> , 19, 227-237	2.7	9
164	Impaired patient-reported outcomes persist in HIV-HCV co-infected patients and in cirrhotic patients despite HCV clearance. <i>Journal of Viral Hepatitis</i> , <b>2018</b> , 25, 314-315	3.4	2
163	Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. <i>International Journal of Drug Policy</i> , <b>2018</b> , 62, 24-29	5.5	4
162	Wine Consumption and Lower Risk of Advanced Liver Fibrosis: A True Effect or Unmeasured Confounding? A Longitudinal Analysis (ANRS CO13 HEPAVIH Cohort). <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1729-1732	0.7	1
161	Changes in supervised drug-injecting practices following a community-based educational intervention: A longitudinal analysis. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 192, 1-7	4.9	5
160	Factors Associated with HIV Status Disclosure in HIV-Infected Sub-Saharan Migrants Living in France and Successfully Treated with Antiretroviral Therapy: Results from the ANRS-VIHVO Study. <i>Journal of Immigrant and Minority Health</i> , <b>2017</b> , 19, 843-850	2.2	7
159	No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVH French cohort). <i>Drug and Alcohol Review</i> , <b>2017</b> , 36, 227-238	3.2	15
158	Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2017</b> , 11, 259-268	4.2	31
157	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 177-188	18.8	59
156	Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 23-31	13.4	40
155	Significant reductions in alcohol use after hepatitis C treatment: results from the ANRS CO13-HEPAVH cohort. <i>Addiction</i> , <b>2017</b> , 112, 1669-1679	4.6	8

154	Health-Related Quality of Life in Chronic HCV-Infected Patients Switching to Pegylated-Interferon-Free Regimens (ANRS CO20 CUPIC Cohort Study and SIRIUS Trial). <i>Patient</i> , <b>2017</b> , 10, 605-614	3.7	4
153	Decrease in self-reported offences and incarceration rates during methadone treatment: A comparison between patients switching from buprenorphine to methadone and maintenance treatment incident users (ANRS-Methaville trial). <i>International Journal of Drug Policy</i> , <b>2017</b> , 39, 86-91	5.5	6
152	Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1157-1167	13.4	18
151	The negative impact of HBV/HCV coinfection on cirrhosis and its consequences. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 1054-1060	6.1	40
150	Role of community-based research in advocating HCV prevention and care. <i>Journal of the International AIDS Society</i> , <b>2017</b> , 20, e25005	5.4	0
149	Suicide risk in a representative sample of people receiving HIV care: Time to target most-at-risk populations (ANRS VESPA2 French national survey). <i>PLoS ONE</i> , <b>2017</b> , 12, e0171645	3.7	17
148	Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France. <i>Substance Abuse Treatment, Prevention, and Policy</i> , <b>2017</b> , 12, 46	3.4	8
147	Thrombosis and antiphospholipid antibody syndrome during acute Q fever: A cross-sectional study. <i>Medicine (United States)</i> , <b>2017</b> , 96, e7578	1.8	15
146	Self-Reported Bothersome Symptoms Across Different Socioepidemiological Groups of People Living With HIV Attending French Hospitals: Results From the ANRS-VESPA2 Survey. <i>Journal of Pain and Symptom Management</i> , <b>2017</b> , 54, 110-119	4.8	5
145	Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study. <i>Harm Reduction Journal</i> , <b>2017</b> , 14, 19	4.6	21
144	Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2017</b> , 41, 56-65	2.4	
143	Unstable Housing Still a Barrier to Receiving HCV Treatment in France (ANRS CO13 HEPAVIH Cohort). <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 2943-2944	4	
142	Pain in methadone patients: Time to address undertreatment and suicide risk (ANRS-Methaville trial). <i>PLoS ONE</i> , <b>2017</b> , 12, e0176288	3.7	7
141	Severe liver disease related to chronic hepatitis C virus infection in treatment-naïve patients: epidemiological characteristics and associated factors at first expert centre visit, France, 2000 to 2007 and 2010 to 2014. <i>Eurosurveillance</i> , <b>2017</b> , 22,	19.8	9
140	De la recherche communautaire à la transformation sociale: l'exemple du projet ANRS-AERLI sur l'accompagnement et l'éducation aux risques liés à l'injection. <i>Psychotropes (discontinued)</i> , <b>2017</b> , 23, 57	0.1	
139	HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks: authors' reply. <i>Aids</i> , <b>2016</b> , 30, 1858-9	3.5	3
138	HIV infection among persons who inject drugs: ending old epidemics and addressing new outbreaks. <i>Aids</i> , <b>2016</b> , 30, 815-26	3.5	76
137	Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, 537-44	11.6	26

136	PASSI d'Argento (Silver Steps): the main features of the new nationwide surveillance system for the ageing Italian population, Italy 2013-2014. <i>Annali Dell'istituto Superiore Di Sanita</i> , <b>2016</b> , 52, 536-542	1.6	4
135	Increased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI Study. <i>PLoS ONE</i> , <b>2016</b> , 11, e0157062	3.7	17
134	Treatment and Prophylactic Strategy for <i>Coxiella burnetii</i> Infection of Aneurysms and Vascular Grafts: A Retrospective Cohort Study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2810	1.8	18
133	Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort). <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 1003-7	2.2	6
132	The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. <i>Liver International</i> , <b>2016</b> , 36, 42-8	7.9	43
131	Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort]. <i>HIV Medicine</i> , <b>2016</b> , 17, 758-765	2.7	4
130	A reduced factor structure for the PROQOL-HIV questionnaire provided reliable indicators of health-related quality of life. <i>Journal of Clinical Epidemiology</i> , <b>2016</b> , 72, 116-25	5.7	6
129	Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. <i>HIV Clinical Trials</i> , <b>2016</b> , 17, 63-71		4
128	B-cell non-Hodgkin lymphoma linked to <i>Coxiella burnetii</i> . <i>Blood</i> , <b>2016</b> , 127, 113-21	2.2	61
127	Tropheryma whipplei DNA in bronchoalveolar lavage samples: a case control study. <i>Clinical Microbiology and Infection</i> , <b>2016</b> , 22, 875-879	9.5	13
126	Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study. <i>Addiction</i> , <b>2016</b> , 111, 94-106	4.6	34
125	Psychometric assessment of health-related quality of life and symptom experience in HIV patients treated with antiretroviral therapy. <i>Quality of Life Research</i> , <b>2015</b> , 24, 1407-18	3.7	8
124	Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 1816-24	5.1	36
123	Increasing access to opioid maintenance treatment: the role of primary care in France. <i>International Journal of Drug Policy</i> , <b>2015</b> , 26, 434-5	5.5	3
122	Cannabis Use and Reduced Risk of Insulin Resistance in HIV-HCV Infected Patients: A Longitudinal Analysis (ANRS CO13 HEPAVIH). <i>Clinical Infectious Diseases</i> , <b>2015</b> , 61, 40-8	11.6	15
121	Comparison of risk factors in HIV-infected men who have sex with men, coinfecting or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). <i>Sexually Transmitted Infections</i> , <b>2015</b> , 91, 21-3	2.8	20
120	Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study). <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2015</b> , 9, 701-13	4.2	4
119	Variations in Cannabis Use Level and Correlates in Opiate-Users on Methadone Maintenance Treatment: A French Prospective Study. <i>Journal of Substance Abuse Treatment</i> , <b>2015</b> , 58, 100-5	4.2	6

118	Scaling up combined community-based HIV prevention interventions targeting truck drivers in Morocco: effectiveness on HIV testing and counseling. <i>BMC Infectious Diseases</i> , <b>2015</b> , 15, 208	4	8
117	Twelve-year mortality in HIV-infected patients receiving antiretroviral therapy: the role of social vulnerability. The ANRS CO8 APROCO-COPILOTE cohort. <i>Antiviral Therapy</i> , <b>2015</b> , 20, 763-72	1.6	5
116	Correlates of general practitioners' recommendations to patients regarding vaccination for the 2009-2010 pandemic influenza (A/H1N1) in France: implications for future vaccination campaigns. <i>Vaccine</i> , <b>2014</b> , 32, 2281-7	4.1	23
115	Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a french paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 65, e148-50	3.1	15
114	Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2014</b> , 26 Suppl 1, S29-40	2.2	25
113	Reevaluation of the risk of fetal death and malformation after Q Fever. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 256-60	11.6	30
112	HCV seropositivity in inmates and in the general population: an averaging approach to establish priority prevention interventions. <i>BMJ Open</i> , <b>2014</b> , 4, e005694	3	10
111	Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2014</b> , 8, 351-8	4.2	5
110	Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfecting patients: possible role of the hepatitis C virus sustained viral response. <i>Aids</i> , <b>2014</b> , 28, 1155-60	3.5	4
109	High levels of alcohol consumption increase the risk of advanced hepatic fibrosis in HIV/hepatitis C virus-coinfecting patients: a sex-based analysis using transient elastography at enrollment in the HEPAVIH ANRS CO13 cohort. <i>Clinical Infectious Diseases</i> , <b>2014</b> , 59, 1190-2	11.6	13
108	Risk factors for adherence failure in HIV-infected sub-Saharan migrants living in France and travelling back to their native country. <i>International Journal of STD and AIDS</i> , <b>2014</b> , 25, 389-90	1.4	3
107	Impact of HCV treatment and depressive symptoms on adherence to HAART among HIV-HCV-coinfecting patients: results from the ANRS-CO13-HEPAVH cohort. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 171-8	1.6	10
106	Predictors of non-adherence to methadone maintenance treatment in opioid-dependent individuals: implications for clinicians. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 4097-105	3.3	36
105	Cocoa and Chocolate: Chemistry, Biochemistry, and Beneficial Brain Effects <b>2013</b> , 389-406		1
104	Prediction of HIV drug resistance based on virologic, immunologic, clinical, and/or adherence criteria in the Stratall ANRS 12110/ESTHER trial in Cameroon. <i>Clinical Infectious Diseases</i> , <b>2013</b> , 57, 604-7	11.6	6
103	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 568-9	3.2	45
102	Health-care-associated bloodstream infections in France. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 656	25.5	4
101	De jure decriminalisation of cannabis use matters: some recent trends from France. <i>International Journal of Drug Policy</i> , <b>2013</b> , 24, 634-5	5.5	4

100	Time to combine intervention with prevention in countries where HIV is also driven by hazardous drinking: The journal publishes both invited and unsolicited letters. <i>Addiction</i> , <b>2013</b> , 108, 221-2	4.6	1
99	Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods. <i>Expert Review of Anti-Infective Therapy</i> , <b>2013</b> , 11, 239-50	5.5	22
98	Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis. <i>Lancet Infectious Diseases</i> , <b>2013</b> , 13, 577-86	25.5	32
97	No condoms for prisoners: accumulating risks of HIV, STI but also hepatitis transmission. <i>Sexually Transmitted Infections</i> , <b>2013</b> , 89, 310	2.8	1
96	Visiting one's native country: the risks of nonadherence in HIV-infected sub-Saharan migrants--ANRS VIHVO study. <i>Journal of the International Association of Providers of AIDS Care</i> , <b>2013</b> , 12, 407-13	1.7	11
95	Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ANRS CO13 cohort). <i>Addiction</i> , <b>2013</b> , 108, 1250-8	4.6	9
94	Factors associated with guideline-based hepatitis C virus (HCV) treatment initiation in HIV/HCV-coinfected patients: role of comorbidities and physicians' perceptions. <i>HIV Medicine</i> , <b>2013</b> , 14, 430-6	2.7	7
93	Changes in sexual activity and risk behaviors among PLWHA initiating ART in rural district hospitals in Cameroon [Data from the STRATALL ANRS 12110/ESTHER trial. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2013</b> , 25, 347-355	2.2	6
92	Task shifting HIV care in rural district hospitals in Cameroon: evidence of comparable antiretroviral treatment-related outcomes between nurses and physicians in the Stratall ANRS/ESTHER trial. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2013</b> , 62, 569-76	3.1	23
91	Time patterns of adherence and long-term virological response to non-nucleoside reverse transcriptase inhibitor regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 29-37	1.6	19
90	Expanding access to non-medicalized community-based rapid testing to men who have sex with men: an urgent HIV prevention intervention (the ANRS-DRAG study). <i>PLoS ONE</i> , <b>2013</b> , 8, e61225	3.7	31
89	20-years of population-based cancer registration in hepatitis B and liver cancer prevention in the Gambia, West Africa. <i>PLoS ONE</i> , <b>2013</b> , 8, e75775	3.7	11
88	Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France). <i>BMC Health Services Research</i> , <b>2012</b> , 12, 59	2.9	9
87	Obesity-associated gut microbiota is enriched in <i>Lactobacillus reuteri</i> and depleted in <i>Bifidobacterium animalis</i> and <i>Methanobrevibacter smithii</i> . <i>International Journal of Obesity</i> , <b>2012</b> , 36, 817-25	5.5	412
86	Empowering HIV testing as a prevention tool: targeting interventions for high-risk men who have sex with men. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2012</b> , 24, 1039-45	2.2	14
85	Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfecting patients: one more argument for expanded access to HCV treatment for injecting drug users. <i>Addiction</i> , <b>2012</b> , 107, 152-9	4.6	14
84	The role of adherence in virological suppression in patients receiving anti-HBV analogues. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 395-400	1.6	27
83	Proximity to HIV is associated with a high rate of HIV testing among men who have sex with men living in Douala, Cameroon. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2012</b> , 24, 1020-7	2.2	7

82	Acceptability of an "on-demand" pre-exposure HIV prophylaxis trial among men who have sex with men living in France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2012</b> , 24, 468-77	2.2	38
81	Performance of HIV care decentralization from the patient's perspective: health-related quality of life and perceived quality of services in Cameroon. <i>Health Policy and Planning</i> , <b>2012</b> , 27, 301-15	3.4	28
80	Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. <i>Annals of Oncology</i> , <b>2012</b> , 23, 882-90	10.3	86
79	Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy. <i>BMJ Open</i> , <b>2012</b> , 2,	3	9
78	Incidence, medical and socio-behavioural predictors of psychiatric events in an 11-year follow-up of HIV-infected patients on antiretroviral therapy. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1079-83	1.6	9
77	The macroeconomic consequences of renouncing to universal access to antiretroviral treatment for HIV in Africa: a micro-simulation model. <i>PLoS ONE</i> , <b>2012</b> , 7, e34101	3.7	17
76	Adherence as a predictor of sexual behaviors in people living with HIV/AIDS during the first year of antiretroviral therapy in rural Cameroon: data from Stratall ANRS 12110/ESTHER trial. <i>PLoS ONE</i> , <b>2012</b> , 7, e36118	3.7	9
75	Non-adherence to aspirin in patients undergoing coronary stenting: negative impact of comorbid conditions and implications for clinical management. <i>Archives of Cardiovascular Diseases</i> , <b>2011</b> , 104, 306-12	2.7	11
74	Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. <i>Drug and Alcohol Dependence</i> , <b>2011</b> , 116, 228-32	4.9	25
73	Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCV-coinfected patients, and factors associated with HAV and HBV vaccination. <i>Vaccine</i> , <b>2011</b> , 29, 8656-60	4.1	14
72	Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial. <i>Lancet Infectious Diseases</i> , <b>2011</b> , 11, 825-33	25.5	74
71	Decentralization of access to antiretroviral therapy in Cameroon: correlates of HIV physicians' knowledge in HIV care. <i>Antiviral Therapy</i> , <b>2011</b> , 16, 423-8	1.6	2
70	Individual and structural factors associated with HIV status disclosure to main partner in Cameroon: ANRS 12-116 EVAL survey, 2006-2007. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 57 Suppl 1, S22-6	3.1	13
69	Adherence to antiretroviral treatment in HIV-positive patients in the Cameroon context: promoting the use of medication reminder methods. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2011</b> , 57 Suppl 1, S40-3	3.1	26
68	Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients. <i>Journal of Viral Hepatitis</i> , <b>2011</b> , 18, e307-14	3.4	31
67	Reduced delays in time to first HIV consultation after diagnosis in France in the antiretroviral therapy era: the possible role of a free care system. <i>HIV Medicine</i> , <b>2011</b> , 12, 383-4	2.7	1
66	Non adherence to thienopyridine after coronary stenting. <i>American Journal of Cardiology</i> , <b>2011</b> , 107, 1866-7	3	1
65	Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 760-5	3	35

64	Determinants of benzodiazepine use in a representative population of HIV-infected individuals: the role of HIV status disclosure (ANRS-EN12-VESPA study). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2011</b> , 23, 1163-70	2.2	5
63	Chronic q Fever detection in the Netherlands. <i>Clinical Infectious Diseases</i> , <b>2011</b> , 53, 1170-1	11.6	14
62	Psychosocial correlates of inconsistent condom use among HIV-infected patients enrolled in a structured ART interruptions trial in Cte d'Ivoire: results from the TRIVACAN trial (ANRS 1269). <i>Tropical Medicine and International Health</i> , <b>2010</b> , 15, 706-12	2.3	13
61	Quality of life assessment in HIV clinical research in resource-limited settings: better late than never. <i>Tropical Medicine and International Health</i> , <b>2010</b> , 15, 1008-10	2.3	
60	Prevalence of unsafe sex with one's steady partner either HIV-negative or of unknown HIV status and associated determinants in Cameroon (EVAL ANRS12-116 survey). <i>Sexually Transmitted Infections</i> , <b>2010</b> , 86, 148-54	2.8	25
59	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. <i>Lancet, The</i> , <b>2010</b> , 376, 340-5 <sup>40</sup>		77
58	Desire for a child among HIV-infected women receiving antiretroviral therapy in Cameroon: results from the national survey EVAL (ANRS 12-116). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2010</b> , 22, 441-51	2.2	12
57	Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepaviv, France, 2006-2008. <i>Journal of Viral Hepatitis</i> , <b>2010</b> , 17, 650-60 <sup>34</sup>		9
56	Higher risk of unsafe sex and impaired quality of life among patients not receiving antiretroviral therapy in Cameroon: results from the EVAL survey (ANRS 12-116). <i>Aids</i> , <b>2010</b> , 24 Suppl 1, S17-25	3.5	22
55	The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010. <i>BMC Infectious Diseases</i> , <b>2010</b> , 10, 303	4	71
54	Quality of Life in HIV Positive Injecting Drug Users <b>2010</b> , 3705-3725		
53	Expanded access to SEPs and other harm reduction measures in France. <i>Addiction</i> , <b>2009</b> , 104, 1447-8	4.6	5
52	Delayed first consultation after diagnosis of HIV infection in Cameroon. <i>Aids</i> , <b>2009</b> , 23, 1015-9	3.5	16
51	Determinants of unplanned antiretroviral treatment interruptions among people living with HIV in Yaounde, Cameroon (EVAL survey, ANRS 12-116). <i>Tropical Medicine and International Health</i> , <b>2008</b> , 13, 1470-8	2.3	51
50	Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: results from South-Eastern France. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2008</b> , 20, 537-41	2.2	17
49	Depressive symptoms and exposure to efavirenz in West African HIV-infected adults. <i>HIV Clinical Trials</i> , <b>2008</b> , 9, 445-7		7
48	20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 3216-23	4	54
47	Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfecting patients. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42, 92-6	3	17

46	Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). <i>International Journal of Drug Policy</i> , <b>2007</b> , 18, 288-95	5.5	31
45	Adding HCV treatment to HIV treatment in HIV-HCV coinfecting patients: the impact on the different dimensions of fatigue and self-reported side effects. <i>Journal of Pain and Symptom Management</i> , <b>2007</b> , 34, 413-21	4.8	15
44	Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. <i>HIV Clinical Trials</i> , <b>2007</b> , 8, 320-7		60
43	Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 2117-23	7.5	111
42	Buprenorphine use: the international experience. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 43 Suppl 4, S197-215	11.6	109
41	Oral contraception and unprotected sex with occasional partners of women HIV-infected through injection drug use. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2006</b> , 18, 795-800	2.2	13
40	The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1157-67	12.9	414
39	Statistical fallibility and the longevity of popes: William Farr meets Wilhelm Lexis. <i>International Journal of Epidemiology</i> , <b>2006</b> , 35, 802-5	7.8	11
38	Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. <i>Transplantation Proceedings</i> , <b>2006</b> , 38, 3533-5	1.1	34
37	Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2006</b> , 41, 477-85	3.1	90
36	Longevity of popes and artists between the 13th and the 19th century. <i>International Journal of Epidemiology</i> , <b>2005</b> , 34, 1435-6	7.8	27
35	Factors associated with efavirenz discontinuation in a large community-based sample of patients. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2004</b> , 16, 558-64	2.2	45
34	Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2004</b> , 16, 649-61	2.2	76
33	Drug injection cessation among HIV-infected injecting drug users. <i>Addictive Behaviors</i> , <b>2004</b> , 29, 1189-97	4.2	34
32	Impact of HAART-related side effects on unsafe sexual behaviours in HIV-infected injecting drug users: 7-year follow up. <i>Aids</i> , <b>2004</b> , 18, 1321-5	3.5	13
31	Blood agar and Mycobacterium tuberculosis: the end of a dogma. <i>Journal of Clinical Microbiology</i> , <b>2003</b> , 41, 1710-1	9.7	35
30	Health-related quality of life after 1 year of highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2003</b> , 32, 38-47	3.1	100
29	Hospitalization for depressive syndrome in a cohort of HIV-infected patients contaminated through injecting drug use: MANIF 2000 cohort, France, 1995-1999. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2003</b> , 15, 729-34	2.2	8

28	Intercenter variability and time of onset: two crucial issues in the analysis of risk factors for nosocomial sepsis. <i>Pediatric Infectious Disease Journal</i> , <b>2003</b> , 22, 599-609	3.4	28
27	Failure to maintain adherence to HAART in a cohort of French HIV-positive injecting drug users. <i>International Journal of Behavioral Medicine</i> , <b>2003</b> , 10, 1-14	2.6	88
26	Reduced incidence of Kaposi's sarcoma and of systemic non-hodgkin's lymphoma in HIV-infected individuals treated with highly active antiretroviral therapy. <i>International Journal of Cancer</i> , <b>2003</b> , 103, 142-4	7.5	56
25	The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. <i>Aids</i> , <b>2003</b> , 17, 1096-9	3.5	15
24	Investigation of a slaughterhouse-related outbreak of Q fever in the French Alps. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2002</b> , 21, 17-21	5.3	39
23	Nonadherence among HIV-infected injecting drug users: the impact of social instability. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 31 Suppl 3, S149-53	3.1	106
22	The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 28, 232-239	3.1	1
21	The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 28, 232-9	3.1	141
20	Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV-Infected Patients Initiating Protease Inhibitors. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2001</b> , 27, 372-376	3.1	40
19	Impact of short-term adherence on virological and immunological success of HAART: a case study among French HIV-infected IDUs. <i>International Journal of STD and AIDS</i> , <b>2001</b> , 12, 324-8	1.4	25
18	Risks factors and prevention of Q fever endocarditis. <i>Clinical Infectious Diseases</i> , <b>2001</b> , 33, 312-6	11.6	224
17	Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. <i>Aids</i> , <b>2001</b> , 15, 2441-4	3.5	205
16	'Do HIV-infected injecting drug users over-report adherence to highly active antiretroviral therapy?' A comparison between patients' self-reports and serum protease inhibitor concentrations in the French Manif 2000 cohort study. <i>Aids</i> , <b>2001</b> , 15, 1075-7	3.5	28
15	Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. <i>Aids</i> , <b>2000</b> , 14, 151-5	3.5	169
14	Cancer risk among men with, or at risk of, HIV infection in southern Europe. <i>Aids</i> , <b>2000</b> , 14, 553-9	3.5	90
13	Evaluation of the SIMI system, an experimental computerised network for the surveillance of communicable diseases in Italy. <i>European Journal of Epidemiology</i> , <b>2000</b> , 16, 941-7	12.1	18
12	Serum Clara cell protein (CC16) in healthy young smokers. <i>Biomarkers</i> , <b>2000</b> , 5, 158-64	2.6	8
11	Impact of drug maintenance treatment on injection practices among French HIV-infected IDUs. The MANIF 2000 Study Group. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , <b>2000</b> , 12, 461-70	2.2	13

10	Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. <i>Journal of Epidemiology and Community Health</i> , <b>1999</b> , 53, 4-8	5.1	70
9	Relationship between HIV-1 viral load and continued drug use in untreated infected injection drug users. <i>Addiction Biology</i> , <b>1999</b> , 4, 197-202	4.6	5
8	Risk of invasive cervical cancer among women with, or at risk for, HIV infection. <i>International Journal of Cancer</i> , <b>1999</b> , 82, 334-7	7.5	77
7	Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy. <i>Clinical Therapeutics</i> , <b>1999</b> , 21, 1313-20	3.5	3
6	Risk of invasive cervical cancer among women with, or at risk for, HIV infection <b>1999</b> , 82, 334		1
5	Mandatory prenatal screening for the human immunodeficiency virus: the experience in south-eastern France of a national policy, 1992-1994. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , <b>1998</b> , 105, 269-74	3.7	14
4	HIV screening for pregnant women in south eastern France: evolution 1992-1994-1996. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , <b>1998</b> , 76, 5-9	2.4	7
3	A case-control study on risk factors for Peyronie's disease. <i>Journal of Clinical Epidemiology</i> , <b>1998</b> , 51, 511-5	5.7	77
2	Risk factors for nosocomial sepsis in newborn intensive and intermediate care units. <i>European Journal of Pediatrics</i> , <b>1996</b> , 155, 315-22	4.1	54
1	Of Rats And Men: Peer Presence And Familiarity Are Key Factors Which Reduce Drug Intake		2